« Back
Home /
Veliparib

Veliparib

Item no.	HY-10129-50mg
Manufacturer	MedChem Express
CASRN	912444-00-9
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 50 mg 5 mg
Category	Food Safety Allergenes Neuroscience Neural Lineage Markers Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.78
Citations	[1]Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37.\|[2]Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201.\|[3]Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. Acta Pharmacol Sin. 2021 Jul 22.\|Biomed Res Int. 2023 Feb 6.\|BMC Cancer. 2022 Mar 23;22(1):312.\|Cancer Discov. 2017 Sep;7(9):984-998.\|Cancer Genet. 2019 Nov;239:26-32.\|Cancers (Basel). 2024 Nov 5;16(22):3728.\|Cancers (Basel). 2024 Oct 10;16(20):3441.\|Cell Death Dis. 2024 Dec 18;15(12):914.\|Cell Signal. 2025 Mar 2:111709.\|Cells. 2021, 10(3), 599.\|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. \|Ecotoxicol Environ Saf. 2023 Mar 1;252:114630.\|Front Mol Biosci. 2021 Apr 29;8:633344.\|Front Oncol. 2021 Jul 9;11:681441.\|Int J Biol Macromol. 2023 May 12;124794.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195.\|J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Transl Med. 2024 Nov 26;22(1):1062.\|J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. \|Mol Cancer Ther. 2019 Nov;18(11):2063-2073.\|Nanomaterials. 2021, 11(6), 1514.\|Nat Commun. 2021 Jun 24;12(1):3931.\|Neoplasia. 2018 Mar 28;20(5):478-488. \|Neoplasia. 2025 Mar 16:63:101152.\|Neoplasia. 2019 Apr 24;21(6):533-544. \|Oncogene. 2022 Aug 6.\|Oncol Lett. 2025 January 7.\|Patent. US20180263995A1.\|Patent. US20180362972A1.\|Research Square Preprint. 2021 Feb.\|Research Square Preprint. 2024 Feb 21.\|Research Square Preprint. 2024 Nov 06.\|Theranostics. 2020 Jul 25;10(21):9477-9494. \|Electrostatics Joint Conference. 2016 July.\|Harvard Medical School LINCS LIBRARY\|Int J Curr Res Acad Rev. 2017; 5(3): 53-64.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Patent. US20200078369A1\|Patent. US20200129476A1
Smiles	O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ABT-888
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Autophagy; PARP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	244.298
Product Description	Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 29 mg/mL
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage; Epigenetics
Isoform	PARP1; PARP2
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10129-50mg-safety-datasheet.pdf